Annotation Detail
Information
- Associated Genes
- ALK
- Associated Variants
- ALK EML4-ALK L1196M
- Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- The crizotinib-resistant MGH045 cell line with EML4-ALK L1196M was treated with crizotinib or ceritinib. In nude mice with MGH045 xenografts, tumor response to crizotinib did not differ appreciably from vehicle, while ceritinib controlled tumor growth. Ceritinib inhibited Ba/F3 cells expressing EML4-ALK L1196M slightly stronger than ALK wild-type, but approximately double the potency as crizotinib, indicating ceritinib sensitivity in Ba/F3 EML4-ALK L1196M cells.
- Variant Origin
- Somatic
- Variant Origin
- somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1341
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1
- Variant URL
- https://civic.genome.wustl.edu/links/variants/7
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Ceritinib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 24675041
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Ceritinib | Sensitivity | true |